“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A study looking at a new treatment plan for locally advanced cancer of the pancreas (PERU)
This study looked at giving a
- GemCap chemotherapy
- followed by capecitabine and radiotherapy
- with or without cetuximab
More about this trial
If you had cancer of the pancreas that had spread to surrounding tissue but not to other parts of the body, you may have had gemcitabine, or a combination of gemcitabine and capecitabine called GemCap.
If this helped, you may then have had radiotherapy. And you may have had capecitabine at the same time. Chemotherapy and radiotherapy together is called
In this study everyone who benefited from GemCap had it followed by chemoradiation. But half the people also had the drug cetuximab during radiotherapy.
Cetuximab is a type of biological therapy called a monoclonal antibody. Monoclonal antibodies can seek out cancer cells by looking for particular proteins.
The main aim of this study was to see which treatment plan worked best for people with locally advanced pancreatic cancer.
Summary of results
While this study was going on another trial called LAP 07 published its results. LAP 07 showed there was no benefit to having chemotherapy followed by chemoradiation for locally advanced pancreatic cancer. And this had an impact on what the PERU study was looking at.
Having considered the LAP 07 results the people who oversaw the study (the Data Monitoring Committee) decided to close the PERU study.
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Ian Chau
Merck Serono UK
The Royal Marsden NHS Foundation Trust